Moderna and Merck’s mRNA Vaccine: A Turning Point for Personalized Cancer Treatment Moderna and Merck announced a significant breakthrough: their personalized mRNA cancer vaccine, when combined with standard therapy, reduced the risk of death Read More
Beyond the Headlines: A Single Dose, A Multi-Decade Question The immediate euphoria surrounding VERVE-102’s interim Phase I results—a staggering 62 percent reduction in LDL cholesterol—misses the most critical elephant in the biotech lab. Read More